Abstract
The compelling need to provide adoptive cell therapy (ACT) to an increasing number of oncology patients within a meaningful therapeutic window makes the development of an efficient, fast, versatile, and safe genetic tool for creating recombinant T cells indispensable. In this study, we used nonintegrating minimally sized DNA vectors with an enhanced capability of generating genetically modified cells, and we demonstrate that they can be efficiently used to engineer human T lymphocytes. This vector platform contains no viral components and is capable of replicating extrachromosomally in the nucleus of dividing cells, providing persistent transgene expression in human T cells without affecting their behavior and molecular integrity. We use this technology to provide a manufacturing protocol to quickly generate chimeric antigen receptor (CAR)–T cells at clinical scale in a closed system and demonstrate their enhanced anti-tumor activity in vitro and in vivo in comparison to
Talent Strategy Director, Universum - Philadelphia: Universum, a Sweden headquartered employer branding consultancy, needed to recruit a new finance director for its business in the Americas based in Philadelphia. Having experience of working with Michael Page in Europe, it was natural for us to reach out to Michael Page’s local Philadelphia office when looking for a partner. Michael Page, and its Philadelphia Manager Brian Pietraccini, quickly understood our business and the requirements of the role. Michael Page showed flexibility, expertise and willingness to commit to us, making it easy for us to give them the assignment on an exclusive basis.